Noxopharm Limited (ASX:NOX)

Market Cap	33.61M
Revenue (ttm)	2.34M
Net Income (ttm)	-2.32M
Shares Out	292.24M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	99,897
Average Volume	439,259
Open	0.1200
Previous Close	0.1200
Day's Range	0.1100 - 0.1200
52-Week Range	0.0430 - 0.1500
Beta	-0.13
RSI	60.07
Earnings Date	Aug 29, 2025

About Noxopharm

Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions. The company als...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NOX

Financial Performance

In 2024, Noxopharm's revenue was 2.40 million, a decrease of -60.06% compared to the previous year's 6.01 million. Losses were -3.58 million, -76.24% less than in 2023.